tirzepatide surpass Once Weekly in Children and Adolescents with Type 2 Diabetes ( SURPASS-Peds). The New England Journal of Medicine. 2024;391:XXX–XXX. doi:10.1056/NEJMoa2400938 SURPASS-CVOT trial: For patients with
Pay in 4 interest-free payments of $6.17 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
SURPASS CVOT trial: For patients with high risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP 1 and glucose dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized SURPASS 2: Tirzepatide bests semaglutide in HbA1c reduction, weight loss SURPASS 5: Tirzepatide lowers HbA1c in adults with type 2 diabetes on insulin glargine Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program Cardiovascular Diabetology Springer Nature Link Post Hoc Analysis of SURPASS 1 to 5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics Diabetes Therapy Springer Nature Link Tirzepatide vs Dulaglutide in T2D: SURPASS CVOT Prof. Dr. Stephen Nicholls (Melbourne, Australia)
Store: businesscommunicationnetwork.com · Domain: businesscommunicationnetwork.com






























